A federal court in Philadelphia granted final approval of two class action settlements worth approximately $70 million, resolving antitrust allegations against Glenmark Pharmaceuticals, Greenstone, and Pfizer for conspiring to inflate generic drug prices.
The settlements conclude litigation claiming the defendants coordinated pricing strategies to artificially elevate costs for generic medications. Class members, including indirect purchasers of affected drugs, will receive compensation from the combined settlement fund. The court's final approval follows preliminary certification of the class and earlier settlement negotiations.
Generic drug price fixing has drawn sustained Department of Justice scrutiny and private litigation over the past decade. Multiple manufacturers have faced similar claims alleging market allocation, bid rigging, and price coordination schemes. These cases typically target older generic drugs with limited competition, where manufacturers can more easily control pricing without detection.
The settlements do not require the defendants to admit wrongdoing but resolve all class claims against them. Individual plaintiffs and state attorneys general may pursue separate claims outside the class action framework. The court's approval reflects its finding that the settlement terms are fair, reasonable, and adequate for class members.
For healthcare purchasers and consumers, these settlements represent partial recovery of excess amounts paid for generic medications. Businesses buying drugs for employee health plans, government agencies, and individual insureds may file claims to recover losses. The settlement process typically requires claimants to submit documentation of purchase records showing purchases of the affected generic drugs during the class period.
The approval underscores ongoing enforcement priorities targeting collusive conduct in the pharmaceutical industry. Federal and state authorities continue investigating generic drug pricing practices. Manufacturers face potential civil damages, criminal prosecution, and regulatory sanctions for participation in pricing conspiracies.